e.weiss
Submits third-party assay reports on material purchased directly. Based in Ibadan.
Section 1
Contribution
Purchases material, pays for assays, and submits the resulting reports to the index.
Records submitted
6
n=6
Annotations
0
n=0
Median purity submitted
98.42%
n=6
Suppliers covered
6
n=6
Section 2
Records submitted
A submitter chose to buy this material and to pay for this assay. That choice is the selection mechanism behind the whole index and it is not random.
| Report | Compound | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041591 | Semaglutide | QSC | QSC-2511-M8005 | Nordanalyt | 2026-Q2 | 99.01 | 3.78 | 90.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042848 | Tirzepatide | GGPeps | GGPE-2510-L2662 | Janoshik | 2026-Q1 | 98.40 | 4.85 | 96.1 | Buyer-sourced | 0 | PASS |
| AX-2025-019718 | Tirzepatide | Homopeptide | HOMO-2510-E3541 | Janoshik | 2025-Q4 | 98.36 | 5.00 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019044 | N-Acetyl Semax Amide | ASY | ASY-{CAT}-2147 | Janoshik | 2025-Q1 | 99.86 | 8.49 | — | Buyer-sourced | 0 | PASS |
| AX-2024-005232 | GHRP-2 | WXT | WXT-2404-N2537 | Nordanalyt | 2024-Q3 | 98.43 | 5.54 | — | Buyer-sourced | 0 | FAIL |
| AX-2024-005079 | SS-31 (Elamipretide) | SSA | SSA-2408-G7111 | Kestrel | 2024-Q3 | 98.29 | 6.20 | 103.1 | Buyer-sourced | 0 | FAIL |